Are there any specific patient profiles in RA or biomarker signatures that would suggest that a patient might respond better to one biologic DMARD and MOA -- including IL-6 inhibition -- versus another?

Are there any specific patient profiles in RA or biomarker signatures that would suggest that a patient might respond better to one biologic DMARD and MOA -- including IL-6 inhibition -- versus another?

Are there any specific patient profiles in RA or biomarker signatures that would suggest that an individual patient might respond better to one biologic DMARD and MOA — including IL-6 inhibition — versus another?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Roy Fleischmann, MD

Roy Fleischmann, MD

Clinical Professor of Medicine
University of Texas Southwestern Medical Center at Dallas
Co-Director, Division of Rheumatology
Texas Health Presbyterian Medical Center and Co-Medical Director
Metroplex Clinical Research Center